Melatonin as an Adjuvant to Antiangiogenic Cancer Treatments

Alicia González1, Carolina Alonso-González1, Alicia González-González1

  • 1Department of Physiology and Pharmacology, School of Medicine, University of Cantabria and Instituto de Investigación Valdecilla (IDIVAL), 39011 Santander, Spain.

Cancers
|July 2, 2021
PubMed

Insights

Melatonin, a hormone, inhibits tumor angiogenesis and enhances chemotherapy sensitivity. It counteracts chemotherapy-induced pro-angiogenic factors, acting as a potential radiosensitizer.

Area of Science:

  • Oncology
  • Endocrinology
  • Cancer Biology

Background:

  • Melatonin is a hormone with studied antitumor properties.
  • Inhibition of angiogenesis is a key antitumor mechanism of melatonin.
  • Melatonin's interaction with chemotherapy and radiotherapy is under investigation.

Purpose of the Study:

  • To review the interaction between melatonin and angiogenesis.
  • To outline mechanisms by which melatonin sensitizes cancer cells to treatment.
  • To explore melatonin's role in overcoming chemotherapy resistance.

Main Methods:

  • Literature review on melatonin's antiangiogenic and radiosensitizing effects.
  • Analysis of melatonin's impact on factors regulating angiogenesis.
  • Examination of synergistic effects of melatonin with chemotherapy and radiotherapy.

Main Results:

  • Melatonin exhibits antiangiogenic effects across various tumor types.
  • Combination therapy with melatonin and chemotherapy shows synergistic antiangiogenic effects.
  • Melatonin counteracts chemotherapy-induced pro-angiogenic factors and enhances tumor cell sensitivity to chemotherapy and radiotherapy.

Conclusions:

  • Melatonin's antiangiogenic properties contribute to its anticancer effects.
  • Melatonin can overcome cancer resistance to chemotherapy.
  • Melatonin acts as a radiosensitizer, enhancing the efficacy of cancer treatments.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.1K